Please try another search
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company’s product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Name | Age | Since | Title |
---|---|---|---|
Man Kin Tam | 45 | 2019 | CFO & Director |
Yiu Leung Cheung | 63 | 2021 | Independent Director |
Peter P. Luo | 57 | 2011 | Co- Founder, Chairman, CEO and President of R&D |
Yan Li | 48 | 2011 | Senior VP of Bioinformatics & Information Technology and Director |
Stanley R. Frankel | 64 | 2021 | Member Scientific & Strategic Advisory Board |
Steven Alan Fischkoff | 72 | 2021 | Member of Scientific & Strategic Advisory Board |
Ulf Grawunder | 58 | 2024 | Independent Director |
Heinz-Josef Lenz | 64 | 2024 | Member of Scientific & Strategic Advisory Board |
Cuong Viet Do | 58 | 2022 | Independent Director |
David R. Gandara | 76 | 2022 | Member Scientific & Strategic Advisory Board |
Yumeng Wang | 33 | 2023 | Director |
Mervyn J. Turner | 75 | 2023 | Independent Director |
Li Zhu | 74 | 2023 | Independent Director |
Robert Jay Spiegel | 75 | 2021 | Member Scientific and Strategic Advisory Board |
Aurelien Marabelle | - | 2023 | Member of Scientific & Strategic Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review